Details for Patent: 9,271,931

Which drugs does patent 9,271,931 protect, and when does it expire?

Patent 9,271,931 protects VYXEOS and is included in one NDA.

This patent has forty-three patent family members in thirteen countries.

Summary for Patent: 9,271,931

Title:	Compositions for delivery of drug combinations
Abstract:	Compositions which comprise delivery vehicles having stably associated therewith non-antagonistic combinations of two or more agents, such as antineoplastic agents, are useful in achieving non-antagonistic effects when combinations of drugs are administered.
Inventor(s):	Tardi; Paul (Surrey, CA), Harasym; Troy (North Vancouver, CA), Webb; Murray (North Vancouver, CA), Shew; Clifford (Vancouver, CA), Janoff; Andrew (Yardley, PA), Bally; Marcel (Bowen Island, CA)
Assignee:	CELATOR PHARMACEUTICALS, INC. (Ewing, NJ)
Application Number:	10/553,373
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,271,931
Patent Claim Types: see list of patent claims	Use; Composition; Delivery; Dosage form;

Drugs Protected by US Patent 9,271,931

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Celator Pharms	VYXEOS	cytarabine; daunorubicin	POWDER;INTRAVENOUS	209401-001	Aug 3, 2017		RX	Yes	Yes			Y

Foreign Priority and PCT Information for Patent: 9,271,931

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Canada	2383259	Apr 23, 2002

PCT Information
PCT Filed	April 16, 2004	PCT Application Number:	PCT/US2004/011812
PCT Publication Date:	November 04, 2004	PCT Publication Number:	WO2004/093795

International Family Members for US Patent 9,271,931

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	345775
Austria	475411
Australia	2002331480
Australia	2002331481
Australia	2002351626
Australia	2004231977